Vimian Group AB AI Stock Analysis
Want to see SE:VIMIAN full AI Analyst Report?
Vimian Group AB (VIMIAN) AI Stock Analysis
Vimian Group AB
(Nasdaq OMX AB:VIMIAN)
The score is driven primarily by solid financial performance (improving profitability and strong free cash flow), partially offset by a high valuation (P/E ~49) and technicals that look overbought (RSI ~79.9, Stoch ~88.1) despite a strong uptrend above key moving averages.
Vimian Group AB (VIMIAN) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 22.07B
- Dividend Yield
- ―
- Average Volume (3M)
- 445.12K
- Price to Earnings (P/E)
- 51.2
- Beta (1Y)
- 0.51
- Revenue Growth
- 8.00%
- EPS Growth
- 20.16%
- Country
- Sweden
- Employees
- 1,300
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Vimian Group AB Business Overview & Revenue Model
Company Description
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfol...
How the Company Makes Money
Vimian makes money primarily by selling veterinary health products and services through its operating subsidiaries to veterinary clinics, hospitals, laboratories, and other animal health customers. Key revenue streams include: (1) Product sales: reve...
Vimian Group AB Financial Statement Overview
Summary
Financial performance is solid, supported by improved profitability since 2022 and strong, consistently positive free cash flow in 2024–2025 and TTM. Key risks are the notable TTM gross margin drop (potential cost/mix pressure) and still-modest returns, while leverage remains moderate but total debt has risen in absolute terms versus 2024–2025.
Income Statement
74PositiveBalance Sheet
71PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 466.29M | 425.00M | 374.80M | 331.73M | 281.31M | 173.35M |
| Gross Profit | 199.97M | 292.80M | 258.30M | 229.43M | 193.99M | 122.85M |
| EBITDA | 127.71M | 104.70M | 82.80M | 75.31M | 39.20M | 36.16M |
| Net Income | 39.26M | 31.30M | 18.50M | 9.84M | -7.20M | 6.59M |
Balance Sheet | ||||||
| Total Assets | 1.20B | 1.11B | 1.11B | 973.68M | 923.56M | 640.72M |
| Cash, Cash Equivalents and Short-Term Investments | 55.90M | 55.00M | 64.80M | 37.50M | 42.19M | 55.11M |
| Total Debt | 281.69M | 238.70M | 233.60M | 313.80M | 220.96M | 180.37M |
| Total Liabilities | 432.29M | 401.00M | 403.30M | 446.97M | 442.06M | 282.08M |
| Stockholders Equity | 751.88M | 698.90M | 699.90M | 526.37M | 481.81M | 357.41M |
Cash Flow | ||||||
| Free Cash Flow | 91.12M | 90.60M | 43.90M | -43.48M | 15.01M | 4.52M |
| Operating Cash Flow | 104.76M | 105.70M | 58.10M | -28.58M | 25.31M | 16.01M |
| Investing Cash Flow | -95.20M | -112.80M | -76.00M | -77.68M | -188.53M | -115.00M |
| Financing Cash Flow | -7.67M | -1.20M | 44.80M | 100.55M | 150.23M | 123.94M |
Vimian Group AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Positive. The current price of 42.25 is above the 20-day moving average (MA) of 40.43, above the 50-day MA of 37.31, and above the 200-day MA of 31.74, indicating a bullish trend. The MACD of 1.46 indicates Negative momentum. The RSI at 72.23 is Negative, neither overbought nor oversold. The STOCH value of 69.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VIMIAN.
Vimian Group AB Peers Comparison
Overall Rating
SE:CEVI83Outperform
SE:ALIF.B74Outperform- SE:VIMIAN66Neutral
SE:DVYSR66Neutral
SE:BACTI.B53Neutral
SE:QLINEA43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CEVI | 83Outperform | SEK 4.84B | 35.03 | 15.23% | 1.36% | 1.95% | -8.91% |
| SE:ALIF.B | 74Outperform | SEK 22.20B | 34.90 | 11.32% | 0.82% | 1.62% | 63.45% |
| SE:VIMIAN | 66Neutral | SEK 22.07B | 51.20 | 5.40% | ― | 8.00% | 20.16% |
| SE:DVYSR | 66Neutral | SEK 1.08B | 43.88 | ― | ― | 4.49% | ― |
| SE:BACTI.B | 53Neutral | SEK 544.93M | 85.56 | 1.93% | ― | -0.51% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:QLINEA | 43Neutral | SEK 264.34M | -1.61 | -48.10% | ― | 33.26% | 90.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:VIMIAN | Vimian Group AB | 42.25 | 11.61 | 37.89% | |
| SE:ALIF.B | AddLife AB Class B | 181.70 | -1.89 | -1.03% | |
| SE:CEVI | CellaVision AB | 202.00 | 45.48 | 29.06% | |
| SE:BACTI.B | Bactiguard Holding AB | 14.55 | -1.65 | -10.19% | |
| SE:QLINEA | Q-linea AB | 13.25 | -11.87 | -47.25% | |
| SE:DVYSR | Devyser Diagnostics AB | 65.00 | -48.60 | -42.78% |
Vimian Group AB Corporate Events
Vimian to Present 2030 Growth Roadmap at November Capital Markets Day
Vimian Group AB will host a Capital Markets Day in Stockholm on 24 November 2026, aimed at institutional investors, analysts and financial media, with management presentations also streamed via live webcast. The event will focus on the company’s stra...
Vimian Delivers Double-Digit Growth and Strengthens Leadership in Q3 2026
Vimian Group AB reported a strong third quarter, with revenue rising 15 per cent to EUR 120.3m, driven by 11 per cent organic growth and supported by acquisitions and favourable currency effects. Operating profit and adjusted EBITA improved, while ca...
Vimian moves into specialised soft tissue surgery with Norfolk Medical acquisition
Vimian Group AB has agreed to acquire Norfolk Medical Products, Inc., a Chicago-based family-owned provider of implants and consumables for veterinary soft tissue surgery in the U.S. Norfolk specialises in implantable solutions for long-term or chron...
Vimian to Present Q3 2026 Interim Results in Investor Audiocast
Vimian Group AB is a global animal health company spanning Specialty Pharma, MedTech, Veterinary Services and Diagnostics, focused on bringing innovative treatments and tools to veterinarians and pet owners across more than 80 markets. With operation...
Vimian adjusts share and vote structure through incentive program issuance
Vimian Group AB reported a change in its capital structure during September, with the number of shares rising to 533,318,550 following the issuance of new D, E1 2026 and E2 2026 share classes under its long-term incentive program LTIP 2026/2029. The...
Vimian Expands 2026 Long-Term Incentive Plan With Additional Share Issue
Vimian Group AB has expanded its long-term incentive program for 2026 by issuing and repurchasing an additional 252,699 shares, comprising class D, class E1 2026 and class E2 2026 shares. The move follows a prior share issue under the program and is...
Vimian Sets Nomination Committee Ahead of 2027 AGM
Vimian Group AB has appointed its Nomination Committee for the 2027 Annual General Meeting, based on the company’s ownership structure as of 31 August 2026. The committee members represent major shareholders Fidelio Capital, Handelsbanken Fonder and...
Vimian appoints new Head of M&A as acquisition-led growth continues
Vimian Group AB has announced a leadership change in its mergers and acquisitions function, appointing Andrea Tidholm as the new Head of M&A effective 5 October, reporting to CFO Carl-Johan Zetterberg Boudrie. Tidholm, currently M&A Director for the...
Vimian adjusts share classes, boosting total voting rights
Vimian Group AB reported a change in its share and vote structure in August following the conversion of 166,405 C shares into an equal number of ordinary shares under the company’s articles of association. This conversion resulted in an increase of 1...
Vimian names Hans Lord Skarplöth to lead Specialty Pharma growth push
Vimian Group AB has appointed Hans Lord Skarplöth as Head of Specialty Pharma and member of the group management team, effective 1 October 2026. Skarplöth, 54, brings nearly three decades of leadership experience, including thirteen years as CEO of A...
Vimian updates share and vote totals after July capital changes
Vimian Group AB has adjusted its capital structure during July through warrant exercises, issuance of incentive-program shares and redemption of certain preference share classes. Following these transactions, the company reports a total of 533,065,85...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026